Particle Sciences Manufactures Clinical Supplies for Kinexs Glioblastoma Therapeutic
Particle Sciences, Inc. (PSI), has completed the manufacturing of clinical supplies for the first in human studies of KX2-361 (KX02), Kinex Pharmaceuticals’ small molecule Src/pre-tublin inhibitor. According to Bruce Frank, Vice President of Project Management at PSI, "PSI’s business has grown to a great degree on the strength of our expanding cGMP manufacturing capabilities. We have worked hard to build a reputation around quality and responsiveness and are excited to help Kinex get this very important drug into the clinic." PSI is a leading CDMO with a focus on highly potent compounds and complex formulations.
"Kinex’s selection of Particle Sciences to help advance this key product into the clinic was based on their excellent reputation, quality of their people, as well as the responsiveness and focus of their organization. I am very proud to say that Particle Sciences has exceeded our expectations and remains a key partner in Kinex’s product development program" commented Mark Seep, Clinical Manufacturing Manager for Kinex Pharmaceuticals, Inc.
"We are pleased that Particle Sciences collaborated with Kinex to manufacture a formulation of KX2-361 for our first in human clinical studies. We are expecting KX2-361 to help address the important unmet medical need of treating brain cancers for the many patients that await therapeutic advances for this serious disease" remarked David Hangauer, Kinex’s Chief Scientific Officer.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance